middle.news
Anteris Raises $320M, Advances DurAVR Trial with US Patient Enrolment
8:54am on Wednesday 13th of May, 2026 AEST
•
Healthcare
Read Story
Anteris Raises $320M, Advances DurAVR Trial with US Patient Enrolment
8:54am on Wednesday 13th of May, 2026 AEST
Key Points
Q1 2026 net loss of $22.9 million
$320 million raised in January 2026
Cash balance surged to $283 million
PARADIGM Trial US enrolment commenced
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Anteris Technologies Global (ASX:AVR)
OPEN ARTICLE